Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home

Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players who have enjoyed success on their own turf will become a global threat.

For all its bluster about the various attractions of emerging markets, pharma’s foray into them has thus far been decidedly one dimensional. Multinationals’ current focus on tapping into new territories to juice top-line growth is understandable, especially given the severity of the business challenges on its home turf and the vast potential opportunities in core developing countries. Their efforts to harness innovation in emerging markets, whether scientific or strategic, have been less forceful, however, and remain largely a longer-term goal.

Yet, how Big Pharma perceives and accesses innovation in emerging markets is critically important to its welfare. Emerging markets offer...

More from Global Vision

More from In Vivo

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.